LC
ONCT

Lindbrook Capital’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Lindbrook Capital’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15
Closed -$20 – 2957
2024
Q3 		$20 Hold
15
– – ﹤0.01% 2814
2024
Q2 		$114 Hold
15
– – ﹤0.01% 2714
2024
Q1 		$135 Hold
15
– – ﹤0.01% 2605
2023
Q4 		$161 Hold
15
– – ﹤0.01% 2650
2023
Q3 		$90 Hold
15
– – ﹤0.01% 2652
2023
Q2 		$104 Hold
15
– – ﹤0.01% 2664
2023
Q1 		$236 Hold
15
– – ﹤0.01% 2712
2022
Q4 		$300 Hold
15
– – ﹤0.01% 2679
2022
Q3 		$0 Hold
15
– – ﹤0.01% 2985
2022
Q2 		$0 Hold
15
– – ﹤0.01% 2845
2022
Q1 		$0 Hold
15
– – ﹤0.01% 2650
2021
Q4 		$1K Buy
+15
New +$1.01K ﹤0.01% 2035

Other funds holding ONCT

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Lindbrook Capital's ONCT Position: Q4 2024 in Review

Lindbrook Capital sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 15 shares — an estimated $20 sold.

Lindbrook Capital first reported a position in ONCT in Q4 2021 and held it in 12 quarters. The position peaked at $1K in Q4 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • Lindbrook Capital reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 15 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $20.
  • Lindbrook Capital first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2021 and held it in 12 quarters.
  • Lindbrook Capital's Oncternal Therapeutics, Inc. Common Stock position peaked at $1K in Q4 2021.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.